Response to Comments: MolDX: Blood Product Molecular Antigen Typing

This document is a response to public comments on MolDX LCD L38331 and records a title revision from 'Erythrocyte Molecular Antigen Typing' to 'Blood Product Molecular Antigen Typing.' The comment period ran 10/22/2019–12/06/2019; the notice period begins 10/22/2020 and the LCD becomes effective 12/06/2020. No specific clinical coverage indications, limitations, documentation requirements for testing, or frequency limits are provided in this response document.

"Response-to-comments document for MolDX LCD L38331 (title revised to 'MolDX: Blood Product Molecular Antigen Typing'); comment period 2019-10-22 to 2019-12-06; notice period begins 2020-10-22; LCD ..."

Sign up to see full coverage criteria, indications, and limitations.